New York Times (May 31)
China’s biotechnology sector passed a milestone. This year’s prestigious meeting of the American Society of Clinical Oncology (ASCO) features “a presentation of a clinical trial conducted only in China.” Typically, the headliners have “featured drug trials that were run mainly at American and European hospitals.” This milestone “reflects the dizzying growth of China’s biotechnology sector. In just a few years, it has transformed from a sleepy industry into a juggernaut rapidly inventing and testing cutting-edge medicines.”
Tags: ASCO, Biotechnology, China, Clinical trial, Cutting-edge medicines, Drug trials, Europe, Growth, Headliners, Inventing, Juggernaut, Milestone, Oncology, Prestigious, Testing, U.S.
Wall Street Journal (August 11)
Though “artificial intelligence has the potential to reinvent the world, from how businesses operate to the types of jobs people hold to the way wars are fought,” the struggles of IBM’s Watson “suggest that revolution remains some way off.” Currently, “no published research shows Watson improving patient outcomes” while “more than a dozen IBM partners and clients have halted or shrunk Watson’s oncology-related projects” because of its “limited impact on patients.” Often, “the tools didn’t add much value. In some cases, Watson wasn’t accurate.”
Tags: Accurate, AI, Clients, IBM, Impact, Oncology, Partners, Patient outcomes, Potential, Revolution, Struggles, Watson
